difference in neutropenia due to administration schedule of tas-102
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

difference in neutropenia due to administration schedule of tas-102

;Yoichiro Yoshida;Naoya Aisu;Ai Mogi;Akira Komono;Ryohei Sakamoto;Daibo Kojima;Toshiyuki Mera;Suguru Hasegawa
multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015 2017 Vol. 10 pp. 226-229
96
yoshida2017casedifference

Abstract

TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by changing to a simple administration method of TAS-102.

Keywords

Chemotherapy colorectal cancer Oncology including cancer and carcinogens tumors neutropenianeoplasms

Access

DOI:
10.1159/000460242
URL:
http://www.karger.com/Article/FullText/460242

Citation

ID: 235642
Ref Key: yoshida2017casedifference
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
235642
Unique Identifier:
10.1159/000460242
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store